Literature DB >> 17451344

HyperPack: a software package for the study of levels, contexts, and patterns of APOBEC-mediated hypermutation in HIV.

Gustavo H Kijak1, Mario Janini, Sodsai Tovanabutra, Eric E Sanders-Buell, Debora L Birx, Merlin L Robb, Nelson L Michael, Francine E McCutchan.   

Abstract

G-to-A hypermutation, a massive substitution of G for A, was first observed in HIV genomes 15 years ago. Initially ascribed to fluctuating nucleotide pools or PCR errors, it has now been recognized as the result of an important host-defense mechanism mediated by APOBECs, a family of sequence-specific cytidine deaminases. Levels of hypermutation vary, and APOBECs have different preferences for the sequence context of cytidines targeted for deamination; analysis of hypermutation provides important information about the host-virus interaction during viral replication. Here we present HyperPack, a software package to support systematic characterization of hypermutated sequences. Users can define the context of substitution for independent study of the effects of different APOBECs. The SubstrateScan and HyperScan modules are overlapping sliding-window strategies to analyze the distribution of targeted motifs and their substitution levels, respectively, across the viral genome. HyperPack is a platform-flexible, Java stand-alone application available through http://www.hivresearch.org/hyperpack/.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451344     DOI: 10.1089/aid.2006.0279

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.

Authors:  Mariana Leão de Lima-Stein; Wagner Tadeu Alkmim; Maria Clara de Souza Bizinoto; Luis Fernandez Lopez; Marcelo Nascimento Burattini; Juliana Terzi Maricato; Leila Giron; Maria Cecília Araripe Sucupira; Ricardo Sobhie Diaz; Luiz Mario Janini
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-25       Impact factor: 2.205

2.  A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads.

Authors:  Elizabeth C Reuman; Severine Margeridon-Thermet; Harrison B Caudill; Tommy Liu; Katyna Borroto-Esoda; Evguenia S Svarovskaia; Susan P Holmes; Robert W Shafer
Journal:  Bioinformatics       Date:  2010-10-11       Impact factor: 6.937

3.  Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Authors:  Andrew E Armitage; Aris Katzourakis; Tulio de Oliveira; John J Welch; Robert Belshaw; Kate N Bishop; Beatrice Kramer; Andrew J McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

4.  APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.

Authors:  Yordanka Kourteva; MariaPia De Pasquale; Tara Allos; Chara McMunn; Richard T D'Aquila
Journal:  Virology       Date:  2012-05-12       Impact factor: 3.616

5.  APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure.

Authors:  Colleen M Holtz; Holly A Sadler; Louis M Mansky
Journal:  Nucleic Acids Res       Date:  2013-04-24       Impact factor: 16.971

6.  Profound differences in virus population genetics correspond to protection from CD4 decline resulting from feline lentivirus coinfection.

Authors:  Abinash Padhi; Howard Ross; Julie Terwee; Sue Vandewoude; Mary Poss
Journal:  Viruses       Date:  2010-12-10       Impact factor: 5.048

7.  A novel Bayesian method for detection of APOBEC3-mediated hypermutation and its application to zoonotic transmission of simian foamy viruses.

Authors:  Frederick A Matsen; Christopher T Small; Khanh Soliven; Gregory A Engel; Mostafa M Feeroz; Xiaoxing Wang; Karen L Craig; M Kamrul Hasan; Michael Emerman; Maxine L Linial; Lisa Jones-Engel
Journal:  PLoS Comput Biol       Date:  2014-02-27       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.